Cohort | Time (Years) | ||||||
---|---|---|---|---|---|---|---|
0.5 | 1 | 2 | 3 | 4 | 5 | ||
A) Elevated-TG analysis | |||||||
Study population with baseline PAD (1) | Proportion | 0.6327 | 0.4965 | 0.3681 | 0.2866 | 0.2444 | 0.2110 |
At risk | 2117 | 1427 | 835 | 547 | 341 | 233 | |
Study population with no baseline PAD (2) | Proportion | 0.6003 | 0.4668 | 0.3338 | 0.2649 | 0.2168 | 0.1841 |
At risk | 11,842 | 7845 | 4428 | 2901 | 1693 | 1138 | |
Comparison group with baseline PAD (3) | Proportion | 0.6182 | 0.4960 | 0.3653 | 0.2994 | 0.2493 | 0.2130 |
At risk | 2022 | 1412 | 825 | 578 | 331 | 229 | |
Comparison group with no baseline PAD (4) | Proportion | 0.5947 | 0.4682 | 0.3406 | 0.2710 | 0.2229 | 0.1903 |
At risk | 11,774 | 7984 | 4589 | 3059 | 1787 | 1206 | |
Clustered P values for between-group comparisons in the elevated-TG analysis | |||||||
1 vs 2 | 1 vs 3 | 1 vs 4 | 2 vs 3 | 2 vs 4 | 3 vs 4 | ||
< 0.001 | 0.911 | 0.001 | < 0.001 | 0.431 | 0.003 | ||
B) High-TG analysis | |||||||
Study population with baseline PAD (1) | Proportion | 0.6279 | 0.4780 | 0.3465 | 0.2677 | 0.2216 | 0.1967 |
At risk | 966 | 622 | 364 | 236 | 144 | 105 | |
Study population with no baseline PAD (2) | Proportion | 0.5849 | 0.4529 | 0.3199 | 0.2522 | 0.2015 | 0.1699 |
At risk | 5499 | 3619 | 2007 | 1309 | 755 | 500 | |
Comparison group with baseline PAD (3) | Proportion | 0.6067 | 0.4925 | 0.3619 | 0.2921 | 0.2418 | 0.2066 |
At risk | 925 | 655 | 377 | 259 | 146 | 103 | |
Comparison group with no baseline PAD (4) | Proportion | 0.5841 | 0.4543 | 0.3283 | 0.2632 | 0.2203 | 0.1903 |
At risk | 5503 | 3673 | 2097 | 1398 | 827 | 547 | |
Clustered P values for between-group comparisons in the high-TG analysis | |||||||
1 vs 2 | 1 vs 3 | 1 vs 4 | 2 vs 3 | 2 vs 4 | 3 vs 4 | ||
0.016 | 0.680 | 0.107 | 0.004 | 0.121 | 0.037 |